Apply on Website
Summit Corporation Limited
Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational? bispecific antibody combining the effects of immunotherapy via a b... Role: Accounting Manager, Category: Accountancy, Size: 51-100
ACCOUNTING MANAGER, R&D: Summit Corporation Limited
Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational? bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.
